|
1
|
Zahir ST and Mirtalebi M: Survival of
patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev.
13:4387–4391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Networ:
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu ZL, Jin BJ, Cheng CG, Zhang FX, Wang
SW, Wang Y and Wu B: Apatinib resensitizes cisplatin-resistant
non-small cell lung carcinoma A549 cell through reversing multidrug
resistance and suppressing ERK signaling pathway. Eur Rev Med
Pharmacol Sci. 21:5370–5377. 2017.PubMed/NCBI
|
|
4
|
Holland JD, Klaus A, Garratt AN and
Birchmeier W: Wnt signaling in stem and cancer stem cells. Curr
Opin Cell Biol. 25:855–863. 2013. View Article : Google Scholar
|
|
5
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGonigle S, Chen Z, Wu J, Chang P,
Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC,
et al: E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits
growth of DNA repair deficient tumors and antagonizes Wnt
signaling. Oncotarget. 6:41307–41323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Busch AM, Johnson KC, Stan RV, Sanglikar
A, Ahmed Y, Dmitrovsky E and Freemantle SJ: Evidence for tankyrases
as antineoplastic targets in lung cancer. Bmc Cancer. 13:2112013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kulak O, Chen H, Holohan B, Wu X, He H,
Borek D, Otwinowski Z, Yamaguchi K, Garofalo LA, Ma Z, et al:
Disruption of Wnt/β-catenin signaling and telomeric shortening are
inextricable consequences of tankyrase inhibition in human cells.
Mol Cell Biol. 35:2425–2435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang C, Zhu H, Sun Z, Xiang Z, Ge Y, Ni C,
Luo Z, Qian W and Han X: Inhibition of Wnt/β-catenin signaling
promotes epithelial differentiation of mesenchymal stem cells and
repairs bleomycin-induced lung injury. Am J Physiol Cell Physiol.
307:C234–C244. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamal A, Riyaz S, Srivastava AK and Rahim
A: Tankyrase inhibitors as therapeutic targets for cancer. Curr Top
Med Chem. 14:1967–1976. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casás-Selves M, Kim J, Zhang Z, Helfrich
BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC
and DeGregori J: Tankyrase and the canonical Wnt pathway protect
lung cancer cells from EGFR inhibition. Cancer Res. 72:4154–4164.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arqués O, Chicote I, Puig I, Tenbaum SP,
Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J,
Silberschmidt D, et al: Tankyrase inhibition blocks Wnt/β-catenin
pathway and reverts resistance to PI3K and AKT inhibitors in the
treatment of colorectal cancer. Clin Cancer Res. 22:644–656. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Voronkov A and Krauss S: Wnt/beta-catenin
signaling and small molecule inhibitors. Curr Pharm Des.
19:634–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polakis P: Drugging Wnt signalling in
cancer. EMBO J. 31:2737–2746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang SM, Mishina YM, Liu S, Cheung A,
Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner
S, et al: Tankyrase inhibition stabilizes axin and antagonizes WNT
signaling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu X, Luo F, Li J, Zhong X and Liu K:
Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon
cancer cell lines via inhibition of the Wnt signaling pathway. Int
J Oncol. 48:1333–1340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lecarpentier Y, Claes V, Duthoit G and
Hébert JL: Circadian rhythms, Wnt/beta-catenin pathway and PPAR
alpha/gamma profiles in diseases with primary or secondary cardiac
dysfunction. Front Physiol. 5:4292014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dregalla RC, Zhou J, Idate RR, Battaglia
CL, Liber HL and Bailey SM: Regulatory roles of tankyrase 1 at
telomeres and in DNA repair: Suppression of T-SCE and stabilization
of DNA-PKcs. Aging (Albany NY). 2:691–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian XH, Hou WJ, Yan F, Fan J, Tong H, Bai
SL, Chen Q, Xu H and Li Y: XAV939, a tankyrase 1 inhibitior,
promotes cell apoptosis in neuroblastoma cell lines by inhibiting
Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 32:1002013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de la Roche M, Ibrahim AE, Mieszczanek J
and Bienz M: LEF1 and B9L shield β-catenin from inactivation by
Axin, desensitizing colorectal cancer cells to tankyrase
inhibitors. Cancer Res. 74:1495–1505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen X, Meng J, Yue W, Yu J, Yang J, Yao Z
and Zhang L: Fibulin-3 suppresses Wnt/β-catenin signaling and lung
cancer invasion. Carcinogenesis. 35:1707–1716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lim JH, Park JW and Chun YS: Human arrest
defective 1 acetylates and activates beta-catenin, promoting lung
cancer cell proliferation. Cancer Res. 66:10677–10682. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Lou Y, Zheng X, Wang H, Sun J,
Dong Q and Han B: Wnt blockers inhibit the proliferation of lung
cancer stem cells. Drug Des Devel Ther. 9:2399–2407.
2015.PubMed/NCBI
|
|
26
|
Thorvaldsen TE, Pedersen NM, Wenzel EM,
Schultz SW, Brech A, Liestøl K, Waaler J, Krauss S and Stenmark H:
Structure, dynamics and functionality of tankyrase
inhibitor-induced degradasomes. Mol Cancer Res. 13:1487–1501. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Lou Y, Zheng X, Wang H, Sun J,
Dong Q and Han B: Wnt blockers inhibit the proliferation of lung
cancer stem cells. Drug Des Devel Ther. 9:2399–2407.
2015.PubMed/NCBI
|
|
29
|
Kahn M: Can we safely target the WNT
pathway? Nat Rev Drug Discov. 13:513–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Riffell JL, Lord CJ and Ashworth A:
Tankyrase-targeted therapeutics: Expanding opportunities in the
PARP family. Nat Rev Drug Discov. 11:923–936. 2012. View Article : Google Scholar : PubMed/NCBI
|
